Antisense oligonucleotide (TTR)
Inotersen
Brand names: Tegsedi
Adult dose
Dose: 284mg SC weekly
Route: SC
Frequency: weekly
Clinical pearls
- Hereditary transthyretin amyloidosis with polyneuropathy; specialist amyloid centre
- Vitamin A 3000 units/day required
Contraindications
- Platelet count <100
- Acute glomerulonephritis
- Severe renal/hepatic impairment
Side effects
- Severe thrombocytopenia (black-box)
- Glomerulonephritis
- Vitamin A deficiency
- Injection site reactions
Interactions
- Antiplatelets/anticoagulants (bleeding)
Monitoring
- Weekly platelet count
- Urinalysis
- U&E
Reference: BNF; NICE HST10; SmPC; https://bnf.nice.org.uk/drugs/inotersen/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO